| Effect | Decrease |
| Trial Design | Cohort |
| Trial Length | 6+ Months |
| Number of Subjects | 61 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average, Underweight |
A pilot study noted that recurrence rates in the group given 45mg MK-4 daily were 12.5% at 12 months, 39.0% at 24 months, and 64.3% at 36 months which significantly outperformed control. The survival rates showed a very strong trend to be improved, but failed to reach statistical significance.
